InvestorsHub Logo
Followers 0
Posts 2258
Boards Moderated 0
Alias Born 12/26/2023

Re: mike00h post# 668228

Sunday, 01/28/2024 10:31:56 PM

Sunday, January 28, 2024 10:31:56 PM

Post# of 719547
*** " However, the trial is not without controversy. Due to a number of well-documented,
interrelated reasons, the trial design included a crossover arm, the use of a
contemporaneous matched external control population (ECP), and a blinded change to its
primary endpoint from Progression-Free Survival (PFS) to Overall Survival (OS)" ***
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News